Previous close | 456.95 |
Open | 454.79 |
Bid | 446.81 x 100 |
Ask | 447.34 x 100 |
Day's range | 445.22 - 454.79 |
52-week range | 320.01 - 457.66 |
Volume | |
Avg. volume | 1,051,004 |
Market cap | 115.319B |
Beta (5Y monthly) | 0.39 |
PE ratio (TTM) | 29.02 |
EPS (TTM) | 15.40 |
Earnings date | 30 Jul 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 467.71 |
On May 22, 2024, Bruce Sachs, Director at Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 7,073 shares of the company.
Cystic fibrosis treatment leader Vertex scored a breakout from a cup base this week, just a few weeks after an earnings beat.
On May 20, 2024, Reshma Kewalramani, CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 15,202 shares of the company, according to the SEC Filing.